TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 224831
Drug: Day treatment
Normalized name: Pharmacist Clotrimazole 3 Day Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day treatment plus drugs
Study: 224831
Drug: Drugs alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs alone
Study: 27810522
Drug: Restarting quadruple
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Restarting quadruple therapy
Study: 27810522
Drug: Average treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average treatment duration
Study: 16459223
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (500 mg daily) and Vitamin C (750 mg daily)
Study: 15225192
Drug: Dydrogesterone 10
Normalized name: dydrogesterone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dydrogesterone 10 mg/day (E + D group, n = 140)
Study: 15225192
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate 5 mg/day (E + P group, n = 139)
Study: 26205910
Drug: Intervention using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention using supplements to increase the intake of EPA and DHA for 12 months
Study: 26205910
Drug: Intervention using
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention using supplements to increase the intake of EPA and DHA
Study: 21921571
Drug: GH 33
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 33 μg/kg/day
Study: 21921571
Drug: GH 67
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 67 μg/kg/day
Study: 17931758
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment (radiochemotherapy)
Study: 17931758
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment (surgery and postoperative radiation)
Study: 12364988
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PP and Reverse Trendelenburg (RT) during laparoscopic GBP
Study: 12364988
Drug: Sequential compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential compression devices during PP and RT in laparoscopic GBP
Study: 12364988
Drug: Sequential compression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential compression devices during RT in open GBP
Study: 8879892
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 250 micrograms twice daily
Study: 6344899
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline (Nuelin SA) 350 mg daily
Study: 6344899
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline (Nuelin SA) 700 mg daily
Study: 31243588
Drug: Triamcinolone hexacetonide
Normalized name: Triamcinolone Hexacetonide
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone hexacetonide (steroid)
Study: 31243588
Drug: Triamcinolone hexacetonide
Normalized name: Triamcinolone Hexacetonide
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone hexacetonide plus tenoxicam (steroid plus tenoxicam)
Study: 27461426
Drug: Asenapine (2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine (2.5-10 mg twice daily)
Study: 18227782
Drug: Family psychoeducational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family psychoeducational treatment
Study: 16002035
Drug: Memantine (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (10, 20, or 30 mg)
Study: 11591884
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (W; 1.2 g/kg/day)
Study: 11591884
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein and creatine monohydrate (WC; 0.1 g/kg/day)
Study: 11591884
Drug: Placebo (P;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (P; 1.2 g/kg/day maltodextrin)
Study: 2649319
Drug: 0.05 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 percent betamethasone dipropionate in optimized cream vehicle applied twice a day
Study: 2649319
Drug: 0.05 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 percent betamethasone dipropionate in optimized cream vehicle applied once a day
Study: 27835048
Drug: Furosemide 20
Normalized name: furosemide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 20 mg OD + nifedipine
Study: 22612061
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose prophylaxis
Study: 22612061
Drug: Additional dose
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional dose 12 hours after prophylaxis
Study: 22612061
Drug: Prophylactic dose
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic dose until nephrostomy tube removal
Study: 15347709
Drug: VEGF gene
Normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: VEGF gene therapy (naked plasmid DNA encoding for human VEGF165)
Study: 15347709
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (direct myocardial revascularization)
Study: 9504354
Drug: Perindopril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (2 mg daily)
Study: 9504354
Drug: Amlodipine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5 mg daily)
Study: 7519554
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous opioid
Study: 3354411
Drug: Oral Lorcainide
Normalized name: tocainide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Lorcainide
Study: 3354411
Drug: Intravenous Lorcainide
Normalized name: lorcainide
DrugBank: Lorcainide (DB13653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Lorcainide
Study: 4335443
Drug: 25-hydroxycholecalciferol (16,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-hydroxycholecalciferol (16,000 IU single oral dose)
Study: 4335443
Drug: 25-hydroxycholecalciferol (varied
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-hydroxycholecalciferol (varied doses)
Study: 27488859
Drug: Prasugrel for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel for 6 weeks at loading/maintenance doses of 20/3.75 mg (Continued Group; n = 68)
Study: 27488859
Drug: Prasugrel at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel at 20/3.75 mg for 2 weeks followed by clopidogrel at 75 mg for 4 weeks (Switched Group; n = 68)
Study: 27488859
Drug: Prasugrel at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel at 20/3.75 mg for 2 weeks followed by clopidogrel at 75 mg for 4 weeks (Switched Group)
Study: 25875843
Drug: 5 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 injections of HIV‐DNA, 1000 μg total dose (3 Env and 2 Gag encoding plasmids)
Study: 25875843
Drug: 2 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 injections of combined HIV‐DNA pools, 600 μg total dose
Study: 25875843
Drug: 2 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 injections with separated pools of HIV‐DNA, 600 μg total dose
Study: 22036862
Drug: Hemoporfin 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoporfin 2.5 mg/kg
Study: 22036862
Drug: Hemoporfin 5
Normalized name: Hemoporfin
DrugBank: Hemoporfin (DB16183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoporfin 5 mg/kg
Study: 22036862
Drug: Hemoporfin 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoporfin 7.5 mg/kg
Study: 22036862
Drug: Hemoporfin 10
Normalized name: Hemoporfin
DrugBank: Hemoporfin (DB16183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoporfin 10 mg/kg
Study: 17176456
Drug: NULL (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: NULL (no drug treatment)
Study: 15630643
Drug: Incisional bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incisional bupivacaine (0.5 ml/kg, 0.25% for <40 kg, 0.5% for >40 kg)
Study: 8977510
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray (1 puff)
Study: 3912182
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg felodipine three times a day
Study: 3912182
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg felodipine three times a day
Study: 24496044
Drug: Pregnenolone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnenolone (50 mg/d)
Study: 16645372
Drug: Ibutilide pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide pretreatment (0.01 mg/kg IV over 10 min)
Study: 1951408
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin 750 mg taken twice daily (n = 52)
Study: 1951408
Drug: Continued parenteral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued parenteral antibiotics (n = 53)
Study: 24374975
Drug: Single-dose vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose vemurafenib (960 mg)
Study: 2007745
Drug: Cisapride 5
Normalized name: cisapride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 5 mg t.i.d. for 12 weeks
Study: 6122970
Drug: Once-monthly rifampicin
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-monthly rifampicin (1,200 mg in a single oral dose) plus daily dapsone (50 mg/day)
Study: 6122970
Drug: Daily rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rifampicin (450 mg/day) plus daily dapsone (50 mg/day)
Study: 6122970
Drug: Once-monthly rifampicin
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-monthly rifampicin (1,200 mg in a single oral dose)
Study: 6122970
Drug: Daily rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily rifampicin (450 mg/day)
Study: 21514398
Drug: Bimosiamose (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimosiamose (10 mg bid)
Study: 16921033
Drug: Early thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early thoracic radiotherapy (TRT) administered concurrently in the second cycle
Study: 16921033
Drug: Late thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late thoracic radiotherapy (TRT) administered concurrently with the sixth cycle
Study: 12835516
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (doxorubicin + DES)
Study: 2059673
Drug: Olsalazine (OLZ)
DrugBank: Olsalazine (DB01250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olsalazine (OLZ) tablets (1g)
Study: 2059673
Drug: Olsalazine (OLZ)
DrugBank: Olsalazine (DB01250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olsalazine (OLZ) capsules (1g)
Study: 6366141
Drug: Alternating combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating combination chemotherapy (vincristine, doxorubicin, alkylating agents, and prednisone)
Study: 6366141
Drug: Alternating combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating combination chemotherapy
Study: 6366141
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy with levamisole
Study: 6366141
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional chemotherapy (melphalan and prednisone)
Study: 26417061
Drug: 90-day use
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90-day use of Vaughan Williams class I or III antiarrhythmic drugs (AAD)
Study: 24614387
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (4000 IU/day of vitamin D3 plus a daily multivitamin containing 400 IU of vitamin D3)
Study: 19175929
Drug: AVI-014 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVI-014 at 4 mcg/kg
Study: 19175929
Drug: AVI-014 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVI-014 at 8 mcg/kg
Study: 19175929
Drug: filgrastim (Neupogen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: filgrastim (Neupogen, Amgen) at 4 mcg/kg
Study: 19175929
Drug: filgrastim (Neupogen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: filgrastim (Neupogen, Amgen) at 8 mcg/kg
Study: 17984247
Drug: Flutamide-metformin (62.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide-metformin (62.5 mg/day + 850 mg/day)
Study: 17984247
Drug: Metformin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin alone (850 mg/day)
Study: 8887604
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 100 microg administered twice a day via a Diskhaler for 3 months
Study: 28623628
Drug: Software-based preference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Software-based preference assessment in addition to the brochure about prostate cancer treatment
Study: 28623628
Drug: Education with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education with a brochure about prostate cancer treatment
Study: 25487185
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of toluidine blue with micropipette followed by 630-nm GaAlAs laser (power density: 10 mW/cm²) during two visits
Study: 25487185
Drug: Mouthwash diluted
Normalized name: phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mouthwash diluted with dexamethasone (tab 0/5 in 5 ml water) for 5 min, followed by rinsing with nystatin 100,000 units for 5 min
Study: 24010987
Drug: 4% prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% prilocaine plain, 5 mg/kg
Study: 24010987
Drug: 2% lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 1:100,000 epinephrine, 2.5 mg/kg
Study: 21396408
Drug: Intranasal trivalent
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal trivalent live attenuated influenza vaccine (LAIV)
Study: 21396408
Drug: Intramuscular trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular trivalent inactivated vaccine (TIV)
Study: 16485884
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide 5%/clindamycin phosphate 1% gel with dimethicone and glycerin
Study: 16485884
Drug: Combination use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination use with topical retinoid
Study: 11534890
Drug: Budesonide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (100 microg or 400 microg) twice daily plus formoterol 9 microg twice daily
Study: 11534890
Drug: Budesonide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (100 microg or 400 microg) twice daily
Study: 9324366
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml of prilocaine 1%
Study: 9324366
Drug: 30 ml
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of prilocaine 1% plus 10 ml bupivacaine 0.5%
Study: 9324366
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml of prilocaine 1% plus 20 ml bupivacaine 0.5%
Study: 2881572
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg ethyl loflazepate
Study: 2881572
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg ethyl loflazepate
Study: 15920748
Drug: Usual diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual diet plus supplements (group 2)
Study: 7749435
Drug: 252 mg
Normalized name: menthol 0.0252 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 252 mg quinacrine pellets
Study: 7749435
Drug: 324 mg
Normalized name: aspirin 324 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 324 mg quinacrine pellets
Study: 7749435
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg quinacrine (previously reported)
Study: 1703909
Drug: rh-EPO at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: rh-EPO at a dose of 3 x 80 U/kg body weight per week
Study: 26445924
Drug: Rosuvastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin treatment for 18 months
Study: 23863036
Drug: Less oxidized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less oxidized omega-3 oil pills
Study: 23863036
Drug: Highly oxidized
Normalized name: Ferrosoferric Oxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly oxidized omega-3 oil pills
Study: 23863036
Drug: No capsules
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No capsules (control group)
Study: 18665696
Drug: Monitoring Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring Group (MG)
Study: 12866115
Drug: Optimal cardiac
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal cardiac medication (controls)
Study: 9168460
Drug: Menhaden oil
Normalized name: MENHADEN OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menhaden oil (6.26 g, n-3 fatty acids) with vitamin E (900 IU)
Study: 9168460
Drug: Menhaden oil
Normalized name: MENHADEN OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menhaden oil (6.26 g, n-3 fatty acids)
Study: 9168460
Drug: Menhaden oil
Normalized name: MENHADEN OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menhaden oil (6.26 g, n-3 fatty acids) with placebo instead of vitamin E
Study: 1550166
Drug: Subcutaneous terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous terbutaline pump
Study: 30808668
Drug: 21 mg
Normalized name: aspirin 421 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg nicotine patches + 18 mg/mL nicotine e‐cigarette
Study: 30808668
Drug: 21 mg
Normalized name: aspirin 421 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21 mg nicotine patches + nicotine free e‐cigarette
Study: 29521661
Drug: Spinal anaesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anaesthesia with 40-mg chloroprocaine 1%
Study: 27354234
Drug: Packaged Cognitive‐Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Packaged Cognitive‐Behavioral Treatment (PCBT)
Study: 23075518
Drug: NeuroFlo™ device
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeuroFlo™ device treatment
Study: 12743579
Drug: Celecoxib (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (10, 30, or 100 mg in suspension)
Study: 12743579
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg administered as two 200-mg doses 2 hours apart)
Study: 9295819
Drug: Somatostatin (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin (3.5 micrograms/kg, 20‐mL bolus) followed by continuous infusion (3.5 micrograms/kg/hr) for 72 hrs
Study: 9295819
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (20‐mL bolus) followed by continuous infusion (20 mL for 30 mins)
Study: 2617153
Drug: Bendroflumethiazide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendroflumethiazide (2.5 mg o.d.)
Study: 31202508
Drug: Ibuprofen acid
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen acid orodispersible tablets (Test product)
Study: 31202508
Drug: Ibuprofen acid
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen acid oral tablets (Reference product)
Study: 31202508
Drug: Ibuprofen S(+)
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen S(+) and R(−) enantiomers
Study: 29395273
Drug: Cannabidiol 20
Normalized name: CANNABIDIOL 20 g in 100 mL ORAL OIL [leafPro CBDmed Oil FS QP 20%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabidiol 20 mg/kg oral daily for 14 weeks
Study: 25148049
Drug: Azithromycin 250
Normalized name: azithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 250 mg daily for 12 weeks
Study: 20101593
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral carbohydrate (OCH)
Study: 18807578
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of omeprazole (20 mg)
Study: 12823078
Drug: Morning light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning light therapy (30 minutes of 400 lux green light treatment)
Study: 12823078
Drug: Citalopram (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (40 mg) with morning light therapy
Study: 12823078
Drug: Citalopram (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (40 mg) with placebo (deactivated negative ion generator)
Study: 9100603
Drug: 5 alpha-dihydrotestosterone
Normalized name: 5.alpha.-hydroxy laxogenin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 alpha-dihydrotestosterone (DHT; 7.0 mg/day)
Study: 8448069
Drug: alpha MeHA,
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha MeHA, 10 mg (as a chloride salt)
Study: 3768929
Drug: 2.5 mg/day
Normalized name: Androderm 2.5 MG/Day 24 HR Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/day of metolazone
Study: 16428156
Drug: 12% salicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12% salicylic acid gel